Replies to post #40454 on Humanigen Inc (HGENQ)

[cowtown jay]

In addition to Cameron and Dale, the other two things we can count on are the efficacy of lenz, and necessity.

"26 states see ‘substantial’ spike in COVID hospitalizations, CDC says
Alix Martichoux
Tue, August 29, 2023"

https://www.yahoo.com/news/26-states-see-substantial-spike-181430641.html

"15 JUN PREACH-M TRIAL: HUMANIGEN STUDY EVALUATES LENZILUMAB AND AZACITIDINE FOR CMML

MedicalResearch.com: What are the main findings?

Response: The study currently has 17 active participants, ten of which were evaluable on June 9, 2023 when the EHA poster was presented, which means they have received at least 3 months of therapy and their hematologic disease parameters have been assessed. All evaluable patients have shown meaningful hematologic improvements and clinical benefit from lenzilumab treatment in addition to azacytidine.

Each parameter (blood monocytes, bone marrow blast percentage, platelet count, blood hemoglobin concentration, and spleen size) has exhibited a durable return to normal or near normal values, with statistical significance. Two of the ten participants have been in the trial for 18 months, the longest of any participants, and exhibit lasting improvement. No participants have relapsed. One participant is now a candidate for stem cell transplantation, which may lead to a potential cure in that patient."

https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/

To address the issue of aGvHD associated with stem cell transplantation, the company has dosed their first patient with this indication.

https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Announces-First-Participant-Dosed-in-RATinG-Trial-of-Lenzilumab-for-Early-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-Allogeneic-Stem-Cell-Transplantation/default.aspx

We already know that the Thorax peer review recognized a Hazard Ratio of 2.54, with a P Value of 0.0009, in lenz for covid, and I hope the supplemental data from ACTIV-5 late stage patients is included with the CMML data in support of additional safety and efficacy the FDA wanted to see for our EUA. We already know the virus has mutated since the new vaccine was designed, and it hasn't even been released yet. They're going to need lenz for this new variant, and the ones that will follow, if we keep using mRNA vaccines.